{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:26:13Z","timestamp":1788909973986,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,30]]},"DOI":"10.7759\/cureus.14764","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T07:01:51Z","timestamp":1619766111000},"source":"Crossref","is-referenced-by-count":7,"title":["Risk of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patient Treated With Natalizumab: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Govinathan","family":"Vivekanandan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansha P","family":"Abubacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revathi","family":"Myneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh V","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimen","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ndakotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/DNND.S203405","article-title":"Progressive multifocal leukoencephalopathy: current insights","volume":"9","author":"Kartau M","year":"2019","unstructured":"Kartau M, Sipil\u00e4 JO, Auvinen E, Palom\u00e4ki M, Verkkoniemi-Ahola A. Progressive multifocal leukoencephalopathy: current insights. Degener Neurol Neuromuscul Dis. 2019, 9:109-121. 10.2147\/DNND.S203405","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"ref2","article-title":"The risk of natalizumab associated PML is revealed: milestones","volume":"3","author":"Kelsey R","year":"2018","unstructured":"Kelsey R. The risk of natalizumab associated PML is revealed: milestones. 2018, 3:5."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/cen3.12440","article-title":"Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: a comprehensive review","volume":"9","author":"Yukitake M","year":"2018","unstructured":"Yukitake M. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: a comprehensive review. Clin Exp Neuroimmunol. 2018, 9:37-47. 10.1111\/cen3.12440","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section","volume":"80","author":"Berger JR","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, et al.. PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology. 2013, 80:1430-1438. 10.1212\/WNL.0b013e31828c2fa1","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww258","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale J","year":"2017","unstructured":"Correale J, Gait\u00e1n MI, Ysrraelit MC, Fiol MP. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain. 2017, 140:527-546. 10.1093\/brain\/aww258","journal-title":"Brain"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058404","article-title":"Natalizumab and progressive multifocal leucoencephalopathy","volume":"65","author":"Berger JR","year":"2006","unstructured":"Berger JR. Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis. 2006, 65:48-53. 10.1136\/ard.2006.058404","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.7513.3","article-title":"The TOUCH program and natalizumab: fundamental flaw in patient protection","volume":"4","author":"Avasarala J","year":"2015","unstructured":"Avasarala J. The TOUCH program and natalizumab: fundamental flaw in patient protection. F1000Res. 2015, 4:1450. 10.12688\/f1000research.7513.3","journal-title":"F1000Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients","volume":"81","author":"Schwab N","year":"2013","unstructured":"Schwab N, Schneider-Hohendorf T, Posevitz V, et al.. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013, 81:865-871. 10.1212\/WNL.0b013e3182a351fb","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20160721","article-title":"Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications","volume":"90","author":"Igra MS","year":"2017","unstructured":"Igra MS, Paling D, Wattjes MP, Connolly DJA, Hoggard N. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. Br J Radiol. 2017, 90:20160721. 10.1259\/bjr.20160721","journal-title":"Br J Radiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/ceor.s6665","article-title":"Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab","volume":"1","author":"Patti F","year":"2009","unstructured":"Patti F, Pappalardo A. Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab. Clinicoecon Outcomes Res. 2009, 1:45-51. 10.2147\/ceor.s6665","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0000000000000005","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study","volume":"72","author":"W\u00fcthrich C","year":"2013","unstructured":"W\u00fcthrich C, Popescu BF, Gheuens S, et al.. Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study. J Neuropathol Exp Neurol. 2013, 72:1043-1051. 10.1097\/NEN.0000000000000005","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3174\/ng.6160182","article-title":"Therapy-associated progressive multifocal leukoencephalopathy during disease-modifying treatment of multiple sclerosis","volume":"6","author":"Krueger KW","year":"2016","unstructured":"Krueger KW, Krueger P, Lehmann HC, Schroeter M. Therapy-associated progressive multifocal leukoencephalopathy during disease-modifying treatment of multiple sclerosis. Neurographics. 2016, 6:350-368. 10.3174\/ng.6160182","journal-title":"Neurographics"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-018-1727-7","article-title":"Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature","volume":"12","author":"Zhang Y","year":"2018","unstructured":"Zhang Y, Wright C, Flores A. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature. J Med Case Rep. 2018, 12:187. 10.1186\/s13256-018-1727-7","journal-title":"J Med Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8217-x","article-title":"Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases","volume":"263","author":"Maas RP","year":"2016","unstructured":"Maas RP, Muller-Hansma AH, Esselink RA, Murk JL, Warnke C, Killestein J, Wattjes MP. Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J Neurol. 2016, 263:2004-2021. 10.1007\/s00415-016-8217-x","journal-title":"J Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1126\/science.148.3676.1477","article-title":"Particles resembling papova viruses in human cerebral demyelinating disease","volume":"148","author":"Zu Rhein GM","year":"1965","unstructured":"Zu Rhein GM, Chou SM. Particles resembling papova viruses in human cerebral demyelinating disease. Science. 1965, 148:1477-1479. 10.1126\/science.148.3676.1477","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686519","article-title":"Electron microscopic observations on a case of progressive multifocal leukoencephalopathy","volume":"5","author":"Silverman L","year":"1965","unstructured":"Silverman L, Rubinstein LJ. Electron microscopic observations on a case of progressive multifocal leukoencephalopathy. Acta Neuropathol. 1965, 5:215-224. 10.1007\/BF00686519","journal-title":"Acta Neuropathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/1073274817729901","article-title":"Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review","volume":"24","author":"Bohra C","year":"2017","unstructured":"Bohra C, Sokol L, Dalia S. Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review. Cancer Control. 2017, 24:1073274817729901. 10.1177\/1073274817729901","journal-title":"Cancer Control"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70006-5","article-title":"Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study","volume":"9","author":"Jilek S","year":"2010","unstructured":"Jilek S, Jaqui\u00e9ry E, Hirsch HH, et al.. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol. 2010, 9:264-272. 10.1016\/S1474-4422(10)70006-5","journal-title":"Lancet Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e31825caf2c","article-title":"Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab","volume":"71","author":"Kleinschmidt-DeMasters BK","year":"2012","unstructured":"Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012, 71:604-617. 10.1097\/NEN.0b013e31825caf2c","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e328346be57","article-title":"Immune reconstitution inflammatory syndrome and the central nervous system","volume":"24","author":"Johnson T","year":"2011","unstructured":"Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol. 2011, 24:284-290. 10.1097\/WCO.0b013e328346be57","journal-title":"Curr Opin Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford DB","year":"2010","unstructured":"Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010, 9:438-446. 10.1016\/S1474-4422(10)70028-4","journal-title":"Lancet Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168376","article-title":"Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian Independent Registry","volume":"11","author":"Prosperini L","year":"2016","unstructured":"Prosperini L, de Rossi N, Scarpazza C, et al.. Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian Independent Registry. PLoS One. 2016, 11:e0168376. 10.1371\/journal.pone.0168376","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4137\/JCNSD.S14049","article-title":"Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis","volume":"6","author":"Hoepner R","year":"2014","unstructured":"Hoepner R, Faissner S, Salmen A, Gold R, Chan A. Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis. J Cent Nerv Syst Dis. 2014, 6:41-49. 10.4137\/JCNSD.S14049","journal-title":"J Cent Nerv Syst Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-311100","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan C","year":"2016","unstructured":"McGuigan C, Craner M, Guadagno J, et al.. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016, 87:117-125. 10.1136\/jnnp-2015-311100","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174858","article-title":"Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?","volume":"12","author":"Kr\u00e4mer J","year":"2017","unstructured":"Kr\u00e4mer J, Tenberge JG, Kleiter I, Gaissmaier W, Ruck T, Heesen C, Meuth SG. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?. PLoS One. 2017, 12:e0174858. 10.1371\/journal.pone.0174858","journal-title":"PLoS One"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/55429-risk-of-progressive-multifocal-leukoencephalopathy-in-multiple-sclerosis-patient-treated-with-natalizumab-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:27:13Z","timestamp":1707506833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/55429-risk-of-progressive-multifocal-leukoencephalopathy-in-multiple-sclerosis-patient-treated-with-natalizumab-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.14764","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,30]]}}}